90 results about "Poliomyelitis" patented technology

The present invention relates to the identification, the isolation and the use of molecules interfering with the function(s) mediated by the poliovirus receptor (PVR) on cells. The molecules can be used for the treatment of cells having a metastatic potential, metastasis and cancer. Further methods are provided that are useful for identifying and isolating molecules which have the capacity to modulate PVR mediated adhesion or invasion potential of cells.

A multi-component vaccine composition is described comprising acellular pertussis vaccine components, diphtheria toxoid, tetanus toxoid and inactivated poliovirus. The composition also may contain a conjugate of a capsular polysaccharide on Haemophilus influenzae type b and tetanus toxoid or diphtheria toxoid, which may be reconstituted from a lyophilized state by the other component. The administration of the multiple component vaccine resulted in no diminution of the immunogenicity of any component as a result of interference by other components of the vaccine.

Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in combination with a pneumococcal conjugate antigen but without an aluminium phosphate adjuvant. A kit may have: (a) a first immunogenic component that comprises an aqueous formulation of a conjugated capsular saccharide from Streptococcus pneumoniae; (b) a second immunogenic component that comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C.

The invention provides a multivalent immunogenic composition containing enterovirus antigens. The composition comprises inactivated EV71 antigens and/or inactivated CA16 antigens, and inactivated polio antigens. The composition can further comprise antigens selected from hepatitis A antigens, hepatitis B antigens, acellular pertussis antigens, tetanus toxoid, diphtheria toxoid, Haemophilus influenzae type b capsular polysaccharide, and meningococcal polysaccharide antigens, as well as physiologically acceptable carriers combined with bacterial polysaccharide antigens. The invention also provides a preparation method of the composition. The composition can prevent invasion of a plurality of pathogens simultaneously without interference among the antigens, and the immunogenicity is no less than that of individually activated antigens. With the composition, vaccination processes are significantly simplified, and the vaccination efficiency is improved with reduced costs.

The invention discloses a gene recombinant vaccine for preventing enterovirus 71 (EV71) infection and a preparation method thereof. The inflection comprises multiple diseases related with the nervous system such as hand-foot-and-mouth disease, paralytic diseases of sterile meningitis, cephalitis and poliomyelitis and the like. Escherichia coli labile enterotoxin B subunit (LTB) is used as an immunological enhancement adjuvant, two fragments of linear neutralizing epitope SP55 and SP70 in EV71 virus coat protein VP1 are used as antigens, prokaryotic expression plasmids of LTB-SP55-SP70 fusion genes are constructed by using gene engineering technology, the plasmids are expressed in escherichia coli, and a recombinant expression product is purified for preparing the EV71 virus gene engineering vaccine.

The invention discloses a vector for expressing protein of poliovirus sample particles and a method for preparing the poliovirus sample particles. The vector contains expression cassettes with the following structures: an arbitrary gene in poliovirus structural proteins VP0, VP1 and VP3 genes is located in the downstream of a promoter 1, and the other two genes are connected by virtue of a 2A sequence and are located in the downstream of a promoter 2, and directions of promoting expressions of the two promoters are opposite. The method for preparing the poliovirus sample particles comprises the following steps: transfecting the carrier to a corresponding host cell, culturing to obtain virus particles or recombinant baculovirus, and infecting the virus to the host cell if the recombinant baculovirus is obtained so as to obtain the virus sample particles. The poliovirus sample particles can be used for respectively inducing high-titer neutralization titer in a body, and can be used as a vaccine for preventing and treating poliovirus infected related diseases.

The invention provides combined vaccine for adsorbing Diphtheria, tetanus and acellular pertussis-Sabin (DTaP-sIPV) inactivated poliovirus and preparation thereof. The DTaP-sIPV is characterized in that each 100ml of the combined vaccine comprises the following components: 400-1800ug (PN) of acellular pertussis (AP) stock solution, 300-700Lf of tetanus toxoid (TT), 1000-2500Lf of diphtheria toxoid (DT), 126-154mg of Al(OH)<3>, 3000-6000DU of sIPV I, 5700-7100DU of sIPV II, 4500-9000DU of sIPV III, 765-935mg of NaCl, 0-600mg of 2-phenoxyethanol and the balance of H<2>O. Compared with the existing products, the DTaP-sIPV has the advantages of higher biological safety, better side reaction and the like; and the DTaP-sIPV has the beneficial effects of preventing a plurality of target diseases, reducing inoculating needles, simplifying immunization programs, improving inoculation rate, reducing opportunity of cross infection, being popular with a majority of parents and children, saving various expenses and facilitating smooth promotion of immunization plan.

The invention relates to a poliovirus type II monoclonal antibody and an application thereof, belonging to the field of immunology and the field of vaccines. In particular, the invention relates to a hybridoma cell strain generating the poliovirus type II monoclonal antibody, the monoclonal antibody produced by the hybridoma cell strain and applications of the hybridoma cell strain and the monoclonal antibody, wherein the collection number of the hybridoma cell strain is CGMCC No.12291.

Live virus vaccines comprise attenuated viruses, while other vaccines comprise killed viruses or parts thereof. It has now been found that the immune response induced by oral poliovirus vaccine (OPV), which is a live vaccine, is cross-reactive with non-polio enteroviruses. OPV is therefore useful in the prevention of non-polio enterovirus diseases, especially Type 1 diabetes mellitus (IDDM). OPV is also useful in combination with killed/subunit non-polio enterovirus vaccines, whereby it prevents harmful side-effects of the killed/subunit vaccine by shifting the immune response from a harmful Th2-type response to a Th1 type response.

The invention relates to a tephromyelitis type I virus monoclonal antibody and application thereof and belongs to the field of immunology and the field of vaccinology. More particularly, the invention relates to a tephromyelitis type I virus monoclonal antibody hybridoma cell strain with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.12292, a monoclonal antibody generated by the hybridoma cell strain and the application of the monoclonal antibody.

The present invention relates to the identification, isolation and use of molecules that interfere with functions mediated by the poliovirus receptor (PVR) on cells. The molecule can be used to treat cells with metastatic potential, metastases and cancer. The present invention further provides methods useful for identifying and isolating molecules capable of modulating PVR-mediated adhesion or invasive potential of cells.

The invention provides a poliovirus vaccine for oral administration. The poliovirus vaccine contains poliovirus antigen, carbohydrate, phosphate and carboxylate. The oral poliovirus vaccine provided by the invention can be adopted to raise stability of the vaccine antigen component, has good stability at temperatures of 37 DEG C, 2-8 DEG C and 25 DEG C, has stable antigen activity, can be used to enhance gastric acid resistance after oral administration of the vaccine finished product, and has good immune response stimulation capability and good safety. The poliovirus vaccine for oral administration contains no other humanized or animal-based protein and has better safety. Meanwhile, the poliovirus vaccine requires low cost, and is suitable for industrial production of the product.

The present invention relates to the field of vaccines for protecting against polio, and in particular to combination vaccines for protecting against polio, diphtheria, tetanus, and pertussis diseases. Specifically, vaccines comprising reduced dose inactivated poliovirus (IPV) is provided, which can maintain an adequate or improved level of protection against polio.

The invention provides an attenuated poliovirus which does not have a base pair mismatch in stem (a) or (b) of domain V of the 5′ non-coding region of its genome, wherein at least seven of the base pairs in stems (a) and (b) are U-A or A-U base pairs.

The present invention provides monoclonal antibodies that recognize polio virus receptor (PVR) and inhibit its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT). The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy, treating infections and in diagnosis.

The invention provides a construction method of a recombinant enterovirus phenotype hybrid system containing a cytokine adjuvant. The construction method comprises the following steps: firstly respectively constructing a VP1 recombinant cell line and a recombinant attenuated enterovirus strain loaded with cytokine genes; then performing infection amplification on the recombinant attenuated enterovirus strain in the VP1 recombinant cell line; the VP1 recombinant cell line is one of or two of VP1 cell lines for expressing an enterovirus type 71 and a coxsackie virus A group type 16; the recombinant attenuated enterovirus strain loaded with the cytokine genes selects from a coxsackie virus group B type 3, the enterovirus type 71 or a poliovirus type I; a cytokine selects from cholera toxin or interferon gamma; recombinant attenuated enteric viruses loaded with the cytokine genes infect the VP1 recombinant cell line, and after a cytopathic effect, progeny viruses are obtained and can activate host immunity to generate immune protection aiming at a variety of intestinal viruses; therefore, the construction method has application values.